Sachetta LLC Takes $52,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sachetta LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 127 shares of the pharmaceutical company’s stock, valued at approximately $52,000.

Other large investors have also recently bought and sold shares of the company. Arlington Trust Co LLC lifted its stake in Vertex Pharmaceuticals by 97.1% during the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the period. Fortitude Family Office LLC purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Baystate Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 25 shares during the period. NBC Securities Inc. purchased a new stake in Vertex Pharmaceuticals in the third quarter valued at $34,000. Finally, Asset Dedication LLC raised its stake in shares of Vertex Pharmaceuticals by 131.8% during the 3rd quarter. Asset Dedication LLC now owns 102 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $443.05 on Wednesday. The business has a 50-day moving average of $410.97 and a 200 day moving average of $405.48. Vertex Pharmaceuticals Incorporated has a 12 month low of $320.01 and a 12 month high of $448.40. The stock has a market capitalization of $114.33 billion, a price-to-earnings ratio of 28.68, a price-to-earnings-growth ratio of 2.13 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 23.08% and a net margin of 39.46%. The company had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. During the same period last year, the business posted $2.67 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 13.3% on a year-over-year basis. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current year.

Insider Activity

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on VRTX. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, April 15th. Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target on the stock in a research report on Thursday, April 11th. Barclays lifted their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, StockNews.com raised shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $432.18.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.